| Entry |
|
|---|
| Name |
Urapidil (JP18/INN);
Ebrantil (TN) |
|---|
| Formula |
C20H29N5O3
|
|---|
| Exact mass |
387.227
|
|---|
| Mol weight |
387.476
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01465 alpha-Adrenergic receptor antagonist
DG01457 alpha1-Adrenergic receptor antagonist
DG01739 Peripherally-acting antiadrenergic
DG03231 Antihypertensive
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
|
|---|
| Remark |
| Product (DG00257): | D01333<JP> |
|
|---|
| Efficacy |
Antidysuria, Antihypertensive, alpha1-Adrenergic receptor antagonist |
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
| hsa04261 | Adrenergic signaling in cardiomyocytes |
| hsa04270 | Vascular smooth muscle contraction |
|
|---|
| Metabolism |
Enzyme: CYP2D6 [HSA: 1565]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07215 | alpha-Adrenergic receptor agonists/antagonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C02 ANTIHYPERTENSIVES
C02C ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING
C02CA Alpha-adrenoreceptor antagonists
C02CA06 Urapidil
D01333 Urapidil (JP18/INN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
214 Antihypertensives
2149 Others
D01333 Urapidil (JP18/INN)
25 Urogenital and anal organ agents
259 Miscellaneous
2590 Miscellaneous
D01333 Urapidil (JP18/INN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01465 alpha-Adrenergic receptor antagonist
DG01457 alpha1-Adrenergic receptor antagonist
DG00257 Urapidil
D01333 Urapidil
DG01739 Peripherally-acting antiadrenergic
DG00257 Urapidil
D01333 Urapidil
DG03231 Antihypertensive
DG00257 Urapidil
D01333 Urapidil
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00257 Urapidil
D01333 Urapidil
Drug classes [BR:br08332]
Cardiovascular agent
DG03231 Antihypertensive
D01333 Urapidil
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRA1
D01333 Urapidil (JP18/INN) <JP>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D01333 Urapidil
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D01333
Drug groups [BR:br08330]
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01465 alpha-Adrenergic receptor antagonist
DG01457 alpha1-Adrenergic receptor antagonist
DG00257 Urapidil
DG01739 Peripherally-acting antiadrenergic
DG00257 Urapidil
DG03231 Antihypertensive
DG00257 Urapidil
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00257 Urapidil
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 28
1 C8x C 17.0199 -22.1795
2 C8x C 17.0199 -20.7792
3 C8y C 18.2356 -20.0790
4 C8y C 19.4442 -20.7792
5 C8x C 19.4442 -22.1795
6 C8x C 18.2356 -22.8797
7 N1y N 20.6573 -20.0798
8 C1x C 20.6560 -18.6863
9 C1x C 21.8693 -17.9869
10 N1y N 23.0816 -18.6881
11 C1x C 23.0804 -20.0885
12 C1x C 21.8672 -20.7877
13 C1b C 24.2947 -17.9888
14 C1b C 25.5070 -18.6898
15 C1b C 26.7203 -17.9907
16 N1b N 27.9325 -18.6917
17 C8y C 29.1458 -17.9923
18 C8x C 29.1429 -16.5921
19 C8y C 30.3562 -15.8928
20 N4y N 31.5685 -16.5940
21 C8y C 31.5675 -17.9944
22 N4y N 30.3542 -18.6936
23 C1a C 30.3521 -20.0939
24 O5x O 32.7796 -18.6954
25 C1a C 32.7818 -15.8947
26 O5x O 30.3572 -14.4924
27 O2a O 18.2373 -18.6786
28 C1a C 17.0553 -17.9940
BOND 30
1 13 14 1
2 4 7 1
3 14 15 1
4 1 2 2
5 15 16 1
6 2 3 1
7 16 17 1
8 3 4 2
9 4 5 1
10 5 6 2
11 7 8 1
12 8 9 1
13 17 18 2
14 18 19 1
15 19 20 1
16 20 21 1
17 21 22 1
18 22 17 1
19 9 10 1
20 22 23 1
21 10 11 1
22 21 24 2
23 11 12 1
24 20 25 1
25 12 7 1
26 19 26 2
27 6 1 1
28 3 27 1
29 10 13 1
30 27 28 1
|
|---|
